Companies unite to bolster diagnostics for cancer and liver disease
Two companies set on making improvements for those with lung cancer, non-alcoholic fatty liver disease…
Two companies set on making improvements for those with lung cancer, non-alcoholic fatty liver disease…
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharma company focused on the development of innovative therapies to…
Despite several high-profile trial failures in the field, multiple players are getting close to the…
With the close of its Series A round at €48M ($54M), the tissue models company…
Medical imaging techniques, such as magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound have…
Biotech company HepaRegeniX has raised a Series B round that will allow its first…
Update (17/12/2019): Promethera has increased the total raised in its Series D round to €47.2M…
Liver diseases are on the rise. Although many drug candidates are being developed, preclinical toxicity,…
Nonalcoholic steatohepatitis (NASH) is the most severe form of nonalcoholic fatty liver disease (NAFLD) and…
Versantis has raised a Series B of €14.6M (CHF 16M) to advance its treatment for…
Developed by the French biotech Genkyotex, a first-in-class treatment for the liver disease primary biliary…
Founded in March this year, Alentis Therapeutics has bagged a Series A round of €11.1M…